{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:57:38Z","timestamp":1788537458770,"version":"build-2803163510"},"reference-count":119,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15265","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T05:00:36Z","timestamp":1757480436000},"page":"1-10","source":"Crossref","is-referenced-by-count":2,"title":["Targeting menin in lysine methyltransferase\u00a0 2A\/nucleophosmin-mutated leukemia: A novel strategy from epigenetic dysregulation to clinical therapy (Review)"],"prefix":"10.3892","volume":"30","author":[{"given":"Junjie","family":"Bi","sequence":"first","affiliation":[{"name":"Department of Hematology, The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou First People's Hospital, Hangzhou, Zhejiang 310053, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, School of Medicine, Affiliated Hangzhou First People's Hospital, Westlake University, Hangzhou, Zhejiang 310000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"key20251007110333_b1-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"16","DOI":"10.6004\/jnccn.2021.0002","article-title":"NCCN guidelines insights: Acute myeloid leukemia, version 2.2021","volume":"19","author":"Pollyea","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"key20251007110333_b2-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: A comprehensive review and 2016 update","volume":"6","author":"De Kouchkovsky","year":"2016","journal-title":"Blood Cancer J"},{"key":"key20251007110333_b3-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am J Hematol"},{"key":"key20251007110333_b4-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"key20251007110333_b5-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41375-024-02246-2","article-title":"Management of isocitrate dehydrogenase 1\/2 mutated acute myeloid leukemia","volume":"38","author":"Fruchtman","year":"2024","journal-title":"Leukemia"},{"key":"key20251007110333_b6-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: New drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov"},{"key":"key20251007110333_b7-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","article-title":"Targeting multiple signaling pathways: The new approach to acute myeloid leukemia therapy","volume":"5","author":"Carter","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"key20251007110333_b8-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/med.21886","article-title":"Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective","volume":"42","author":"Pei","year":"2022","journal-title":"Med Res Rev"},{"key":"key20251007110333_b9-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.molcel.2023.11.014","article-title":"DNA damage and transcription stress","volume":"84","author":"Milano","year":"2024","journal-title":"Mol Cell"},{"key":"key20251007110333_b10-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.semcancer.2022.10.002","article-title":"The role of transcription factors in the acquisition of the four latest proposed hallmarks of cancer and corresponding enabling characteristics","volume":"86","author":"Morgan","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"key20251007110333_b11-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41568-021-00411-8","article-title":"Targeting transcription cycles in cancer","volume":"22","author":"Vervoort","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"key20251007110333_b12-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.trecan.2023.08.012","article-title":"Chemical-genetics refines transcription factor regulatory circuits","volume":"10","author":"Layden","year":"2024","journal-title":"Trends Cancer"},{"key":"key20251007110333_b13-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/s41589-023-01270-0","article-title":"Remodeling oncogenic transcriptomes by small molecules targeting NONO","volume":"19","author":"Kathman","year":"2023","journal-title":"Nat Chem Biol"},{"key":"key20251007110333_b14-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1101\/gad.350314.122","article-title":"SPOC domain proteins in health and disease","volume":"37","author":"Appel","year":"2023","journal-title":"Genes Dev"},{"key":"key20251007110333_b15-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"key20251007110333_b16-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"K\u00fchn","year":"2016","journal-title":"Cancer Discov"},{"key":"key20251007110333_b17-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1038\/s41375-024-02368-7","article-title":"Menin inhibitors in pediatric acute leukemia: A comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community","volume":"38","author":"Cuglievan","year":"2024","journal-title":"Leukemia"},{"key":"key20251007110333_b18-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0092-8674(00)80967-8","article-title":"Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription","volume":"96","author":"Agarwal","year":"1999","journal-title":"Cell"},{"key":"key20251007110333_b19-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature10806","article-title":"The same pocket in menin binds both MLL and JUND but has opposite effects on transcription","volume":"482","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"key20251007110333_b20-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-023-00826-6","article-title":"Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1","volume":"13","author":"Fiskus","year":"2023","journal-title":"Blood Cancer J"},{"key":"key20251007110333_b21-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"key20251007110333_b22-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ccell.2020.02.011","article-title":"It's all about MEis: Menin-MLL inhibition eradicates NPM1-Mutated and MLL-rearranged acute leukemias in mice","volume":"37","author":"Gundry","year":"2020","journal-title":"Cancer Cell"},{"key":"key20251007110333_b23-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"key":"key20251007110333_b24-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"T147","DOI":"10.1530\/ERC-17-0298","article-title":"Epigenetic regulation by the menin pathway","volume":"24","author":"Feng","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"key20251007110333_b25-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccr.2008.05.003","article-title":"Menin critically links MLL proteins with LEDGF on cancer-associated target genes","volume":"14","author":"Yokoyama","year":"2008","journal-title":"Cancer Cell"},{"key":"key20251007110333_b26-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.3390\/ijms25116020","article-title":"Distinct responses to menin inhibition and synergy with DOT1L inhibition in KMT2A-rearranged acute lymphoblastic and myeloid leukemia","volume":"25","author":"Adriaanse","year":"2024","journal-title":"Int J Mol Sci"},{"key":"key20251007110333_b27-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"e28284","DOI":"10.1002\/pbc.28284","article-title":"Evaluation of VTP-50469, a menin-MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium","volume":"67","author":"Kurmasheva","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"key20251007110333_b28-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1001\/jama.2023.16503","article-title":"Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: A randomized clinical trial","volume":"330","author":"Nicholls","year":"2023","journal-title":"JAMA"},{"key":"key20251007110333_b29-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib","volume":"59","author":"Groenland","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"key20251007110333_b30-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41388-024-02976-8","article-title":"SIRT7: A novel molecular target for personalized cancer treatment?","volume":"43","author":"Ianni","year":"2024","journal-title":"Oncogene"},{"key":"key20251007110333_b31-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.3390\/cancers14194611","article-title":"Role of sirtuins in the pathobiology of onco-hematological diseases: A PROSPERO-registered study and in silico analysis","volume":"14","author":"Goes","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20251007110333_b32-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jhep.2013.07.011","article-title":"Hepatic menin recruits SIRT1 to control liver steatosis through histone deacetylation","volume":"59","author":"Cao","year":"2013","journal-title":"J Hepatol"},{"key":"key20251007110333_b33-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s11033-012-2326-0","article-title":"The tumor suppressor protein menin inhibits NF-\u03baB-mediated transactivation through recruitment of Sirt1 in hepatocellular carcinoma","volume":"40","author":"Gang","year":"2013","journal-title":"Mol Biol Rep"},{"key":"key20251007110333_b34-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1161\/STROKEAHA.113.001715","article-title":"Silent information regulator 1 protects the brain against cerebral ischemic damage","volume":"44","author":"Hern\u00e1ndez-Jim\u00e9nez","year":"2013","journal-title":"Stroke"},{"key":"key20251007110333_b35-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1016\/j.apsb.2023.02.018","article-title":"Nimbolide targeting SIRT1 mitigates intervertebral disc degeneration by reprogramming cholesterol metabolism and inhibiting inflammatory signaling","volume":"13","author":"Teng","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"key20251007110333_b36-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00011-024-01890-9","article-title":"Sirt1 inhibits macrophage polarization and inflammation in gouty arthritis by inhibiting the MAPK\/NF-\u03baB\/AP-1 pathway and activating the Nrf2\/HO-1 pathway","volume":"73","author":"Zhao","year":"2024","journal-title":"Inflamm Res"},{"key":"key20251007110333_b37-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.12659\/MSM.900754","article-title":"Sirtuin 1 (Sirt1) overexpression in BaF3 cells contributes to cell proliferation promotion, apoptosis resistance and pro-inflammatory cytokine production","volume":"23","author":"Wang","year":"2017","journal-title":"Med Sci Monit"},{"key":"key20251007110333_b38-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4161\/adip.23437","article-title":"Sirtuin-1 is a nutrient-dependent modulator of inflammation","volume":"2","author":"Kotas","year":"2013","journal-title":"Adipocyte"},{"key":"key20251007110333_b39-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-022-01257-8","article-title":"The sirtuin family in health and disease","volume":"7","author":"Wu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"key20251007110333_b40-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1182\/blood-2014-12-619783","article-title":"Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation","volume":"125","author":"Alinari","year":"2015","journal-title":"Blood"},{"key":"key20251007110333_b41-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"116857","DOI":"10.1016\/j.ejmech.2024.116857","article-title":"Overview of the PRMT6 modulators in cancer treatment: Current progress and emerged opportunity","volume":"279","author":"Peng","year":"2024","journal-title":"Eur J Med Chem"},{"key":"key20251007110333_b42-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41392-018-0009-6","article-title":"Detection of PRMT1 inhibitors with stopped flow fluorescence","volume":"3","author":"Qian","year":"2018","journal-title":"Signal Transduct Target Ther"},{"key":"key20251007110333_b43-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3390\/cells9091973","article-title":"Fine-Tuning of GLI activity through arginine methylation: Its mechanisms and function","volume":"9","author":"Abe","year":"2020","journal-title":"Cells"},{"key":"key20251007110333_b44-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1158\/0008-5472.CAN-12-3158","article-title":"Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome","volume":"73","author":"Gurung","year":"2013","journal-title":"Cancer Res"},{"key":"key20251007110333_b45-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"key":"key20251007110333_b46-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41580-022-00483-w","article-title":"Establishment of H3K9-methylated heterochromatin and its functions in tissue differentiation and maintenance","volume":"23","author":"Padeken","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20251007110333_b47-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.bbrc.2014.07.113","article-title":"The role of tumor suppressor menin in IL-6 regulation in mouse islet tumor cells","volume":"51","author":"Song","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"key20251007110333_b48-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"e152673","DOI":"10.1172\/JCI152673","article-title":"Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia","volume":"132","author":"Mei","year":"2022","journal-title":"J Clin Invest"},{"key":"key20251007110333_b49-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1159\/000354194","article-title":"Impact of interleukin-6 in hematological malignancies","volume":"40","author":"Burger","year":"2013","journal-title":"Transfus Med Hemother"},{"key":"key20251007110333_b50-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12032-021-01498-7","article-title":"The role of various interleukins in acute myeloid leukemia","volume":"38","author":"Kaser","year":"2021","journal-title":"Med Oncol"},{"key":"key20251007110333_b51-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol Ther"},{"key":"key20251007110333_b52-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12964-023-01039-x","article-title":"Jak2\/STAT6\/c-Myc pathway is vital to the pathogenicity of Philadelphia-positive acute lymphoblastic leukemia caused by P190(BCR-ABL)","volume":"21","author":"Qin","year":"2023","journal-title":"Cell Commun Signal"},{"key":"key20251007110333_b53-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.3390\/cancers14143557","article-title":"NF-\u03baB: A druggable target in acute myeloid leukemia","volume":"14","author":"Di Francesco","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20251007110333_b54-ol-30-5-15265","first-page":"683","article-title":"Understanding the Wnt signaling pathway in acute myeloid leukemia stem cells: A feasible key against relapses","volume":"12","author":"L\u00e1inez-Gonz\u00e1lez","year":"2023","journal-title":"Biology (Basel)"},{"key":"key20251007110333_b55-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"101118","DOI":"10.1016\/j.currproblcancer.2024.101118","article-title":"Menin signaling and therapeutic targeting in breast cancer","volume":"51","author":"Liu","year":"2024","journal-title":"Curr Probl Cancer"},{"key":"key20251007110333_b56-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1229e1","DOI":"10.1161\/CIRCULATIONAHA.112.000826","article-title":"Deletion of the activated protein-1 transcription factor JunD induces oxidative stress and accelerates age-related endothelial dysfunction","volume":"127","author":"Paneni","year":"2013","journal-title":"Circulation"},{"key":"key20251007110333_b57-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"6434","DOI":"10.1038\/sj.onc.1205822","article-title":"Menin uncouples Elk-1, JunD and c-Jun phosphorylation from MAP kinase activation","volume":"21","author":"Gallo","year":"2002","journal-title":"Oncogene"},{"key":"key20251007110333_b58-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1136\/gut.52.9.1237","article-title":"Keeping neuroendocrine cells in check: Roles for TGFbeta, Smads, and menin?","volume":"52","author":"Dockray","year":"2003","journal-title":"Gut"},{"key":"key20251007110333_b59-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1055\/s-2005-870152","article-title":"Menin and TGF-beta superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast","volume":"37","author":"Hendy","year":"2005","journal-title":"Horm Metab Res"},{"key":"key20251007110333_b60-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.tibs.2013.05.005","article-title":"Menin: A scaffold protein that controls gene expression and cell signaling","volume":"38","author":"Matkar","year":"2013","journal-title":"Trends Biochem Sci"},{"key":"key20251007110333_b61-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"40267","DOI":"10.1074\/jbc.M401312200","article-title":"Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2","volume":"279","author":"Sowa","year":"2004","journal-title":"J Biol Chem"},{"key":"key20251007110333_b62-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-018-0008-7","article-title":"Targeting oncogenic Myc as a strategy for cancer treatment","volume":"3","author":"Chen","year":"2018","journal-title":"Signal Transduct Target Ther"},{"key":"key20251007110333_b63-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.cell.2008.04.043","article-title":"Integration of external signaling pathways with the core transcriptional network in embryonic stem cells","volume":"133","author":"Chen","year":"2008","journal-title":"Cell"},{"key":"key20251007110333_b64-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"15278","DOI":"10.1038\/ncomms15278","article-title":"Menin enhances c-Myc-mediated transcription to promote cancer progression","volume":"8","author":"Wu","year":"2017","journal-title":"Nat Commun"},{"key":"key20251007110333_b65-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"key":"key20251007110333_b66-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1158\/0008-5472.CAN-22-0671","article-title":"FOXR2 is an epigenetically regulated pan-cancer oncogene that activates ETS transcriptional circuits","volume":"82","author":"Tsai","year":"2022","journal-title":"Cancer Res"},{"key":"key20251007110333_b67-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"e2307953","DOI":"10.1002\/advs.202307953","article-title":"Menin deficiency induces autism-like behaviors by regulating foxg1 transcription and participates in foxg1-related encephalopathy","volume":"11","author":"Zhuang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"key20251007110333_b68-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1016\/j.celrep.2017.02.025","article-title":"Enhancer-mediated oncogenic function of the menin tumor suppressor in breast cancer","volume":"18","author":"Dreijerink","year":"2017","journal-title":"Cell Rep"},{"key":"key20251007110333_b69-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.2337\/db17-0885","article-title":"Human proislet peptide promotes pancreatic progenitor cells to ameliorate diabetes through FOXO1\/menin-mediated epigenetic regulation","volume":"67","author":"Jiang","year":"2018","journal-title":"Diabetes"},{"key":"key20251007110333_b70-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/path.4885","article-title":"Foxa2, a novel protein partner of the tumour suppressor menin, is deregulated in mouse and human MEN1 glucagonomas","volume":"242","author":"Bonnavion","year":"2017","journal-title":"J Pathol"},{"key":"key20251007110333_b71-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","article-title":"Wnt\/\u03b2-catenin signaling, disease, and emerging therapeutic modalities","volume":"169","author":"Nusse","year":"2017","journal-title":"Cell"},{"key":"key20251007110333_b72-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1039\/D1CB00063B","article-title":"Wnt signaling activation: Targets and therapeutic opportunities for stem cell therapy and regenerative medicine","volume":"2","author":"Bonnet","year":"2021","journal-title":"RSC Chem Biol"},{"key":"key20251007110333_b73-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"dev146589","DOI":"10.1242\/dev.146589","article-title":"Wnt signaling in development and tissue homeostasis","volume":"145","author":"Steinhart","year":"2018","journal-title":"Development"},{"key":"key20251007110333_b74-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"key20251007110333_b75-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"e2405758","DOI":"10.1002\/advs.202405758","article-title":"Targeting the NOTCH2\/ADAM10\/TCF7L2 Axis-mediated transcriptional regulation of Wnt pathway suppresses tumor growth and enhances chemosensitivity in colorectal cancer","volume":"12","author":"Xiang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"key20251007110333_b76-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1038\/s41467-024-45616-1","article-title":"Dysregulation of Wnt\/\u03b2-catenin signaling contributes to intestinal inflammation through regulation of group 3 innate lymphoid cells","volume":"15","author":"Hao","year":"2024","journal-title":"Nat Commun"},{"key":"key20251007110333_b77-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"20099","DOI":"10.1038\/s41598-023-47139-z","article-title":"Tripartite motif 31 drives gastric cancer cell proliferation and invasion through activating the Wnt\/\u03b2-catenin pathway by regulating Axin1 protein stability","volume":"13","author":"Feng","year":"2023","journal-title":"Sci Rep"},{"key":"key20251007110333_b78-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s13046-021-02058-7","article-title":"MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and \u03b2-catenin","volume":"40","author":"Luo","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"key20251007110333_b79-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/nprot.2007.243","article-title":"Quantitative analysis of chromosome conformation capture assays (3C-qPCR)","volume":"2","author":"Hag\u00e8ge","year":"2007","journal-title":"Nat Protoc"},{"key":"key20251007110333_b80-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1093\/hmg\/ddv032","article-title":"CHD6 regulates the topological arrangement of the CFTR locus","volume":"24","author":"Sancho","year":"2015","journal-title":"Hum Mol Genet"},{"key":"key20251007110333_b81-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1186624","article-title":"The Wnt\/beta-catenin pathway is required for the development of leukemia stem cells in AML","volume":"327","author":"Wang","year":"2010","journal-title":"Science"},{"key":"key20251007110333_b82-ol-30-5-15265","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20211841","article-title":"Targeting \u03b2-catenin in acute myeloid leukaemia: Past present, and future perspectives","volume":"42","author":"Wagstaff","year":"2022","journal-title":"Biosci Rep"},{"key":"key20251007110333_b83-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1158\/1535-7163.MCT-20-0115","article-title":"Therapeutic vulnerabilities of transcription factors in AML","volume":"20","author":"Khan","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"key20251007110333_b84-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.semcancer.2020.12.007","article-title":"Nuclear receptors: Lipid and hormone sensors with essential roles in the control of cancer development","volume":"73","author":"Font-D\u00edaz","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"key20251007110333_b85-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.trecan.2020.11.007","article-title":"Targeting nuclear receptors for cancer therapy: Premises, promises, and challenges","volume":"7","author":"Yang","year":"2021","journal-title":"Trends Cancer"},{"key":"key20251007110333_b86-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.3892\/mmr.2015.4159","article-title":"Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis","volume":"12","author":"Lian","year":"2015","journal-title":"Mol Med Rep"},{"key":"key20251007110333_b87-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1016\/j.cell.2021.08.036","article-title":"ER\u03b1 is an RNA-binding protein sustaining tumor cell survival and drug resistance","volume":"184","author":"Xu","year":"2021","journal-title":"Cell"},{"key":"key20251007110333_b88-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12672-023-00808-x","article-title":"Delineating the role of nuclear receptors in colorectal cancer, a focused review","volume":"15","author":"Manickasamy","year":"2024","journal-title":"Discov Oncol"},{"key":"key20251007110333_b89-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41419-021-04205-6","article-title":"Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth","volume":"12","author":"Sun","year":"2021","journal-title":"Cell Death Dis"},{"key":"key20251007110333_b90-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1002\/cac2.12217","article-title":"The scaffold protein menin is essential for activating the MYC locus and MYC-mediated androgen receptor transcription in androgen receptor-dependent prostate cancer cells","volume":"41","author":"Luo","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"key20251007110333_b91-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1002\/mco2.104","article-title":"NF-\u03baB signaling in inflammation and cancer","volume":"2","author":"Zhang","year":"2021","journal-title":"MedComm (2020)"},{"key":"key20251007110333_b92-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/cr.2010.183","article-title":"NF-\u03baB and STAT3 - key players in liver inflammation and cancer","volume":"21","author":"He","year":"2011","journal-title":"Cell Res"},{"key":"key20251007110333_b93-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1038\/sj.emboj.7600244","article-title":"Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase","volume":"23","author":"Yeung","year":"2004","journal-title":"EMBO J"},{"key":"key20251007110333_b94-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"key20251007110333_b95-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/d41573-024-00198-x","article-title":"FDA approves first biparatopic antibody therapy","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"key20251007110333_b96-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: From bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"key":"key20251007110333_b97-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1038\/s41375-023-02037-1","article-title":"The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: Are they druggable in AML?","volume":"37","author":"Falini","year":"2023","journal-title":"Leukemia"},{"key":"key20251007110333_b98-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"key20251007110333_b99-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"key20251007110333_b100-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"key20251007110333_b101-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.canlet.2019.11.005","article-title":"KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease","volume":"469","author":"Forgione","year":"2020","journal-title":"Cancer Lett"},{"key":"key20251007110333_b102-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1128\/MCB.21.1.224-234.2001","article-title":"Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia","volume":"21","author":"Thorsteinsdottir","year":"2001","journal-title":"Mol Cell Biol"},{"key":"key20251007110333_b103-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat Chem Biol"},{"key":"key20251007110333_b104-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"key":"key20251007110333_b105-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41392-023-01627-w","article-title":"Targeting menin: A promising therapeutic strategy for susceptible acute leukemia subtypes","volume":"8","author":"Di Fazio","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"key20251007110333_b106-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-024-01632-8","article-title":"Menin inhibitors for the treatment of acute myeloid leukemia: Challenges and opportunities ahead","volume":"17","author":"Nadiminti","year":"2024","journal-title":"J Hematol Oncol"},{"key":"key20251007110333_b107-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"972606","DOI":"10.3389\/fonc.2022.972606","article-title":"Targeted therapy in NPM1-mutated AML: Knowns and unknowns","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"key20251007110333_b108-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov"},{"key":"key20251007110333_b109-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","article-title":"Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia","volume":"13","author":"Wang","year":"2023","journal-title":"Cancer Discov"},{"key":"key20251007110333_b110-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"key":"key20251007110333_b111-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41375-023-01882-4","article-title":"Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1","volume":"37","author":"Mill","year":"2023","journal-title":"Leukemia"},{"key":"key20251007110333_b112-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/blood.2024026232","article-title":"Menin inhibitors in the treatment of acute myeloid leukemia","volume":"145","author":"Huls","year":"2025","journal-title":"Blood"},{"key":"key20251007110333_b113-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-Rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"key20251007110333_b114-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol"},{"key":"key20251007110333_b115-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/s41375-024-02312-9","article-title":"Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations","volume":"38","author":"Miao","year":"2024","journal-title":"Leukemia"},{"key":"key20251007110333_b116-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1182\/blood.2023022832","article-title":"BRG1\/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor","volume":"143","author":"Fiskus","year":"2024","journal-title":"Blood"},{"key":"key20251007110333_b117-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"key":"key20251007110333_b118-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13045-024-01573-2","article-title":"Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting","volume":"17","author":"An","year":"2024","journal-title":"J Hematol Oncol"},{"key":"key20251007110333_b119-ol-30-5-15265","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood.2021012806","article-title":"The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML","volume":"139","author":"Heikamp","year":"2022","journal-title":"Blood"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T08:04:23Z","timestamp":1759824263000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":119,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9,10]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15265","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}